StemCell Therapy

About Conference

Euro Personalized Medicine 2019Conference welcomes the Professors, Pathologists, Specialists,Clinical Geneticist, Cytogenetic Diagnostics, Therapists, Researchers Specialized from Molecular Genetics and Genomics, Physicians and Hospitalists with different specialties such as Endocrinologist, Cardiologist,Nephrologist, Orthopaedic, Haematologists, Immunologists,Oncologists, Rheumatologist, Research scholars, Industrial professionals and Student delegates from Biomedical, Pharmaceuticals and Telemedicine and Healthcare Sectors to be a part of it, from all over the world to Rome Italy . We are delighted to invite you all to attend and register at 10thEuropean Conference on Predictive Preventive and Personalized Medicine & Molecular Diagnostics " which is going to be held during August 29-30, 2019, in London UK.

The theme of the conference isExploring Innovations in advancing Personalized Medicine and Bio-Markers.Euro Personalized Medicine is a multidisciplinary field, interesting and interactive scientific sessions have been designed accordingly for this conference which includes the diagnosis, care and management of different acute and chronic medical conditions, comprises of various medical specialties such as cardiac health issues, brain disorders, digestive diseases, blood disorders, respiratory diseases, different types of cancers , immunological andinfectious diseases, basically all minor and major health issues which requires short and long-term, comprehensive care.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Euro Personalized Medicine -2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Euro Personalized Medicine-2019 organizing committee look forward to meeting you in Euro Personalized Medicine -2019.

Conference Series Ltd has an enhanced and highlighted features of scientific partnerships and alliances with development agencies, Institutes, leading research organizations, non-government organizations, and other entities to promote the development-oriented research acrossthe globe through live streaming, B2B and Scientific Meetings. Conference Series LtdsMedical Conferencesprovides an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster. Conference Series Ltd Organizes 300+Scientific Conferencesevery year across USA, Europe & Asia. Besides 500 Peer reviewed, Open Access Journals, Conference Series Ltd has collaborated with more than 1000Scientific Associationsand institutions worldwide to promote information on health care and technologies. These journals are enjoying the support of over 5 million readers; a team of 30.000 eminent scholars is providing editorial support.

Importance and scope:It estimated that 57 countries have an absolute shortage of 2.3 million physicians and nurses, midwives. This shortage of primary health care professionals suggests that many countries have insufficient numbers of health professionals to deliver essential health interventions. The shortage is defined as having a projected supply of primary physicians that meet less than 80% of the forecasted primary care demand or need, calculated at estimated means.

Who is Attending?

WHAT IS IT?

Preventive Medicine

Preventive healthcare consists of measures taken fordisease prevention, as opposed to disease treatment. Amedicineor other treatment designed to prevent disease or ill healths. Which is affected by environmental factors, genetic predisposition, disease agents, and lifestyle choices

Predictive Medicine

The branch of medical science or practice concerned with the prediction of the occurrence or course of disease in individual patients, now especially usinggeneticinformation.

Molecular diagnostics

Molecular diagnostics method used to analyzebiological markersin the genome and proteome and by applying molecular biology to medical testing. This technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients.

Personalized medicine

Personalized medicineis amedicalpractice that separates patients into different groups withmedicaldecisions, practices, interventions, and products being tailored to the individual patient based on their predicted response andrisk of disease.

Personalized Medicinealludes as an individualized treatment which implies the solution of particular medications and therapeutics. Personalized Medicine 2019 highlights the topic"Exploring Innovations in advancing Personalized Medicine and Bio-Markers"alongside the logical system clears an approach to assembling visionaries through the exploration talks and presentations. A definitive mission of the meeting is to advance numerous interesting the Novel Approaches and Innovations in customized prescription and social insurance, serves a motivation for the progression ofMolecular Diagnostics, a brief talk on Protein Biomarkers, extraordinary spotlight onGeneticsInformed PersonalizedImmunotherapyandStem CellsTherapy as the Future of Personalized Medicine. Customized Medicine guarantees numerous restorative advancements, and can possibly change the way medications are found and utilized.

Conference Series Ltdis devotedly involved in conducting 300+Conference Series Ltd Every Year across Europe, USA (Baltimore, Chicago, Las Vegas, Philadelphia, and San Antonio) and almost all other parts of the world with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Personalized medicine therapeuticsand companion diagnostic market have huge opportunities for growth in healthcare and will improve therapeutic effectiveness and reduce the severity of adverse effects approach todrug therapies. Personalized cancer medicine is self-made samples of translating cancer genetics into medical. There is a huge contribution ofGenomic medicineby revealing genomic variations; have an effect on health, sickness and drug response.Biomarkeralso plays vital role in the biological characteristic which can be molecular, anatomic, physiologic and chemical change drug development research which turns biomarkers intocompanion diagnostics.

Benefits of Attending the Conference

Supporting Journals:

Contact Person:

Andriana Samron

Program Manager | Euro Personalized medicine 2019

Phone:1-702-508-5200 x 8036

The 10thEuropeanConference onPredictive Preventive and Personalized Medicine & Molecular Diagnostics will be held on August 29-30, 2019 in London, UK will be organized around the themeExploring Innovations in advancing Personalized Medicine and Bio-Markerswhichcomprises 23 Sessions/Tracksto outline the theme of the conference organized byconference series llc LTDConferences. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Track 1:Molecular Diagnostics in Personalized Medicine

In personalized medicinemolecular diagnosticsis used for analysing of biological markers and also analysing by applying molecular biology to medical testing .This technique is used to diagnose and monitordisease, detect risk in individual patients .DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule .SNP genotyping is the measurement ofgeneticvariations of single nucleotide polymorphism (SNPs).which is the measurement of more generalgeneticvariation. Gene expression profiling is used for the measurement ofthe activity of thousands of genes at once.

Related Associations:

Alzheimers and Dementia Testing for Earlier Diagnosis

Association for Molecular Pathology Establishes New Standard for Clinical Utility of Molecular Diagnostics

British In Vitro Diagnostics Association (BIVDA)

California Life Sciences Association- Molecular Diagnostics

American Board of Clinical Chemistry

Molecular Diagnostics Laboratory

Association for Molecular pathology

Track2:Biomarkers Personalized Medicine

In personalized medicinebiomarkersand biological markergenerally refers to a measurableindicator of some biological state or condition. This wordrefers to a substance the presence of which indicates the existence of aliving organism. Biochemical biomarkers are often used inclinical trials, Biomarkers used forpersonalized medicineare typically categorized as either prognostic or predictive .In, a biomarkersis a molecule that allows the detection and isolation of a particular cell type. Abiomarkerindicates a change instate of a protein that correlates with the risk or progression of a disease . Biomarkers are useful in a number of ways, including measuring the progress ofdisease. Biomarkers also used inearlydiagnosis, disease prevention, drug target identification, drug response etc.

Related Associations:

ALS research Association

European society of cardiology

American Association of Pharmaceutical Scientists

American Board of Clinical Chemistry

Track3:Pharmacogenetic in Personalized Medicine

In personalized medicinepharmacogeneticsis the study of inherited genetic differences in drug metabolic pathways which can affect the drug responses, like therapeutic effect as well as adverse effect. Inter- and intra-individual variation ingene expressionand its function.In oncology,pharmacogeneticsrefers to germline mutations andpharmacogenomicsis study the somatic mutations in tumoral DNA leading to alteration in drug response

Related Associations:

European Society of Pharmacogenomics and Personalized Medicine

American Society of Human Genetics

Hungarian Society of Personalized Medicine

American Society for Investigative Pathology

Association for Molecular Pathology

Track4:Pharmacogenomics in Personalized Medicine

Pharmacogenomicsis the study of the role of genetics in drug response. It deals with the influence of acquired and inheritedgeneticvariation on drug response, drug absorption distribution, metabolism, and elimination ,as well as drug receptor target effects .Pharmacogenomicsis often used interchangeably with pharmacogenetics.Pharmacogenomics is used for the detection of the individualgeneticvariation with drug responsespharmacogeneticsfocuses on single drug-gene interactions, incorporatinggenomicsand epigenetics while dealing with the effects of multiplegeneson drug response

Related Associations:

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

Track5:Pharmacoproteomics in Personalized Medicine

Theproteomeis the entire set ofproteinsit is expressed by genome , cell, tissue, or organism at a certain time. More specifically, it is a combined of proteins and genomes .Proteomicsis the study of the proteome. Acellularproteome is the collection of proteins present in a particularcelltype and it exposure to harmone stimulation . It can also be useful to consider an organisms complete proteome, which can be conceptualized as the complete set of proteins from all of the various cellularproteomes. Proteome used to refer to the collection of proteins in certain sub-cellularbiological systems.

Related Associations:

International precision medicine Associates

International Society of Personalized Medicine

British Society for Proteome Research

European Proteomics Association

Swiss Proteomics Society

Japan Society for clinical Proteomics

Track6:Metabolomics in Personalized Medicine

Metabolomicsis defined as the chemical processes involving of metabolites. Metabolomics is the study of the unique chemical fingerprints. Themetabolomerefers to the collection of all metabolites in a biological cell, tissue, organ or organism. mRNA gene expression data and proteomic analyses reveals the set of gene products in the cell. One of the challenges of system biology and functional genomics is to integrate proteomic ,transcriptomic, andmetabolomicinformation to provide acellular biology.

Related Associations:

Metabolomics Society

The Metabolomics Standards Initiative (MSI)

Metabolomics for a Low Carbon Society (METABOLOMICS)

Swiss Metabolomics Society

Metabolomics Research Group (MRG)

Track7:Personalized in Health Care

Personalized medicineis aMedical Practicethat separates patients into different groups with medical decisions, practices, interventions and products being tailored to the individual patient based on their predicted response or risk of disease. The words of personalized medicine,precision medicine,stratified medicineand P4 medicine are used interchangeably .

Related Associations:

American Health Care Association

Florida Health Care Association

OHCA Oregon Health Care Association

Texas Health care Association

Washington Health Care Association

Track8:Non- genomics Personalized Medicine

Epigenomicsis a set of epigenetic modifications on the genetic material of a cell is called as the epigenome. Epigenetics are reversible modifications on a cells DNA that affect the gene expression without altering the DNA sequence.Epigeneticmodifications are important role in the gene expressionand regulation, that are involved in the numerouscellularprocesses such as tumorigenesis.

Related Associations:

Genome Wide Association Studies (GWAS)

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

German society of Human Genetics

Track9:Personalized Biological Therapies

Biological therapyrefers to the use of medication , specifically target an immune orgeneticmediator of disease. Even for diseases of unknown cause of molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. which are mainly cytokines , are directly involved in the immune system .Biological therapyused for the management of cancer , autoimmune disease, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

Read more here:
Euro Personalized Medicine Conferences 2019 | Molecular ...

Genomic medicine has long offered the promise of gene-based disease prevention and treatmentallowing medical providers to successfully predict, prevent, and treat disease based upon an individuals genetic or biomarker information. And while we are a long way from the fountain of youth, personalized medicine, also known as precision medicine, is no longer a future-situated hypothetical; many physicians even offer genetic testing at routine wellness visits. But personalized medicine triggers a host of questions for life sciences companies to sort through (i.e. manufacturing, commercializing, etc.), not the least of which pertain to quality and regulatory concerns.

While the practice of medicine has always been personalizedindividual patients treated based on their health profiles and disease markersthe evolving field of personalized and precision medicine involves more refined diagnostic testing than traditional medicine. And treatment is tailored to the patient after accounting for the patients unique biological, physiological, and environmental profiles. As defined by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), personalized medicine is the use of genetic or other molecular biomarker information to improve the safety, effectiveness, and health outcomes of patients via more efficiently targeted risk stratification, prevention, and tailored medication and treatment management approaches.

But given the departure from one-size-fits-all or trial and error diagnostic and treatment models, unique quality assurance challenges arise. For instance, how can adverse event tracking models apply to highly tailored treatments specific to each patients unique biology? How can clinicians and pathologists ensure that specimens remain valid and reliable throughout processing? And how will companies absolutely ensure the safety of protected health information that will increasingly include patients individual genetic code? These questions are generating a lot of buzz in the world of personalized and precision medicine and will continue to do so in the coming years.

Ironically, though the prevalence of adverse events theoretically decreases with the targeted provision of personalized medicine, a new problem of tracking adverse events emerges. While adverse event tracking in traditional medicine involves large sets of variable data, in personalized medicine, the number of variables is vastly increased.

Sophisticated big data analytics will continue to play an important role in adverse event detection, developing efficient flows of information and complex algorithmic solutions to assist pharmaceutical and biotech companies as well as regulators in successfully interacting with adverse event data.

A celebrated tenet of personalized medicine is that only treatments likely to benefit the patient are administered. But it was discovered that unreliable specimens led to inaccurate HER2 tests in up to 20 percent of cases, leading to inappropriate breast cancer treatment decisions. As a result, guidelines were established to ensure proper specimen-handling. However, such guidelines are not the norm vis--vis specimen processing and there is generally a lack of standardization as specimens travel from patient to pathologist.

As this issue becomes more visible, watch for further guidance from the following authorities: the American Society of Clinical Oncology (ASCO) as well as other professional organizations; the World Health Organization (WHO); the FDA; and the Centers for Medicare and Medicaid Services (CMS).

Another challenge for pharmaceutical and other life sciences companies is anticipating the regulations related to personalized healthcare, including gene and cell therapy. As human cell and gene therapy-related research and development rapidly expands, all stakeholders must watch for equally rapid shifts in regulations.

For the third year in a row, more than 25% of all new molecular entities (NMEs) approved by the FDAs Center for Drug Evaluation and Research (CDER) in 2016 were personalized medicines. And July 2017 saw the FDAs approval of Kymriah, Novartis CAR-T gene therapy, indicating the FDAs readiness to support personalized medicine. However, with novel biologic products comes minimal long-term evidence of safety and efficacy as well as a dearth of treatment experience. This doesnt help in alleviating uncertainty around the future of regulatory action and market viability of such personalized treatments.

Lately, many international workshops have convened to address the emerging regulatory issues pertaining to cell therapy while regulatory bodies have published guidance for cell therapy productsincluding several guidance documents added by the FDA in late 2017.

The well-known provision for real world evidence (RWE) in the recent 21st Century Cures Act (the Cures Act) has the potential for a major impact on the approvals of personalized medicine products. Given the non-traditional treatment profile of a gene therapy, RWE is especially helpful in assessing personalized medicines long-term benefits and risks in clinical practice. Under the sixth installment of the Prescription Drug User Fee Act (PDUFA VI), the FDA has committed to speeding the drug approval process by hiring more highly qualified experts as well as facilitating a more well-established use of real-world evidence to support post market drug safety surveillance by instating a new safety review system.

As with many emerging technologies, the enthusiasm surrounding personalized medicine is tempered by uncertainties in quality and regulatory schemas. As the shift to personalized medicine is younger than the laws that otherwise regulate the medical and research fields, there are frustrating gaps between technology and oversight. But these gaps should narrow while companies continue to make reasonable assumptions while they wait. As always, all stakeholders must remain vigilantly abreast of quality and regulatory developments as personalized medicine shows promise as the future of healthcare. Vigilance is of particular import to the many smaller developers of personalized medicines that may have limited resources or regulatory support.

Stakeholders must remember that regulatory views differ on a global basis, including between the FDA and the EMA. We expect a common set of principles to emerge as personalized medicine continues to secure its foothold as an accepted field of medical treatment.

If you found this information interesting, subscribe to our blog to receive the latest insights, like this one:

Excerpt from:
Personalized Medicine: Quality and Regulatory Issues

PhRMAs member companies are on the leading edge of personalized medicine development an area that is transforming health care, improving patient outcomes and creating health system efficiencies. In a new video, Dr. Bernie Zeiher, president of development of Astellas, discusses his excitement around the promise of personalized medicine, which uses diagnostic tools to help assess the medical treatments and procedures that may be best for each patient.

I am very optimistic about the future because the promise of personalized medicine has begun to be seen, Dr. Zeiher says in the video. Now, with more personalized-type therapies, you can test the tumor or test the blood to determine that in fact the person has a particular mutation, and then that will guide which therapy you would choose and it also increases the likelihood that the patient will respond.

Dr. Zeihers enthusiasm reflects the commitment of Americas biopharmaceutical companies to the development of these targeted treatments. Although there were only 13 FDA-approved personalized medicines in 2006, today there are more than 140. Additionally, personalized medicines accounted for more than 25 percent of FDA approvals last year, marking a record year for these innovative therapies.

Cancer is an area where personalized medicines are having a particularly big impact, driving tremendous advances for patients with highly aggressive cancers, like non-small cell lung cancer (NSCLC). In fact, research has shown nearly two-thirds of NSLCs have a genetic mutation that can be more effectively targeted with a personalized medicine.

Thanks to the hard work of biopharmaceutical researchers, like Dr. Zeiher, 42 percent of medications currently in the pipeline have the potential to be personalized. While the science has never been more complex, the future of research is bright with personalized medicine becoming a reality.

Read the rest here:
The Promise of Personalized Medicine | Innovation.org

Research can take a long time; therefore, we cannot guarantee that we will find information in your sample to return to you. As more samples are processed and genotyping is completed, the Biobank may find information that is medically important for some participants. This information is about genetic variations or changes in DNA that may affect how a person reacts to certain types of medications or that may increase risk of certain diseases, such as cancer or heart disease. For many of these diseases, there are medical options to reduce risk or manage the effects of disease.

If we learn something about your sample, such as information on your risk of certain diseases or health conditions, how you may respond to medications or your risk of being a carrier of certain diseases, we may be able to return this to you. We will ask your permission first before returning any information to you. However, not everyone will have this information, so we cannot guarantee that everyone will receive results

See original here:
Colorado Center for Personalized Medicine

Personalized medicine is gaining recognition due to limitations with standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored treatment for individual patients based on their genetic signatures and clinical characteristics. Advances in whole genome sequencing have allowed the identification of genes involved in a large number of diseases, and biomarkers that indicate disease severity or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential for translation into personalized medicine, in terms of estimating both disease risk and response to therapy. This article collection covers recent advances in personalized medicine across all areas of medical science and clinical practice, demonstrating that patient-tailored treatment is being employed for some diseases, whereas more work is required to translate scientific advances into the clinic for others. We are seeking submissions of original research, reviews and debates offering insights into new advances in this exciting area of medicine.

Read the original:
Personalized medicine: genes, biomarkers and tailored treatment

Personalized medicine are drugs that are based on individual patient or intended patient groups carrying certain biomarkers and are created to cater the requirement of an individual patient based on the response produced by the patient suffering from a particular disease. The personalized medicines are currently in focus due to their effectiveness in cancer patients and patients suffering from rare genetic disorders. The fact that this approach could do away with the One Size Fits All approach leads to anticipations regarding higher treatment effectiveness through customization of prevention, prediction and treatments. In this regard, funds worth EUR 1 Bn has been invested by the EU as of 2015, focused on the development of personalized medicine, through its Seventh Framework Program for Research and Technological Innovation. The EU is also known to be coordinating with the member states on Health Technology Assessment for better understanding on cost-benefit-efficiency of including personalized medicines in their respective health systems. Constructive dialogue among global stakeholders could streamline the clinical trial processes and regulations regarding the same over the forthcoming years.

Personalized Medicine Market: Drivers & Restraints

Personalized medicine market is expected to witness rapid growth due to increasing disease incidence and deep focus of creating medicines for cancer patients where effectiveness has been proved to be higher as compared to other therapies. Rapid results & customized effects, lower probability of medication flaws and adverse drug reactions are some of the other factors that could create suitable traction in both R&D and revenue potential for these medicines. Favorable policies of the governments in relation to the personalized medicine will also add incremental opportunity to exploit this market. Recent developments in the pharmacogenomics are expected to create suitable environment for developing drugs, which are specific to one patient or group. Development of genetic databases could provide additional boost to the market. Upcoming therapeutic application opportunities in fields such as cardio-renal, neurology, antiviral, pulmonary, psychiatry among others could create R&D traction across all regions.

Complex nature of the drugs, high development costs, sub-optimal development framework and inter-patient variability of effects are some of the restraints that could hamper revenue growth of the personalized medicines market over the forthcoming years.

Personalized Medicine Market: Segmentation

This market can be segmented on the basis of Therapeutic area, End user and Application as follows:

Segmentation based on Therapeutic area

Oncology

Neurology

Cardiology

Antiviral

Psychiatry

Others

Segmentation based on End User

Hospitals

Molecular Diagnostic Laboratories and Testing facilities

Academic Institutes, clinical care and Research Laboratories

Contract Research Organizations

Bio and health informatics companies

Others (Service providers, partners, venture capitalists, etc.)

Segmentation based on Application

Companion Diagnostics

Biomarker identification

Health Informatics

Clinical Research

Personalized Medicine Market: Overview & Region wise Outlook

This market is mainly driven by increasing disease incidence of various cancers and other autoimmune diseases during the forecast period. The major growth in revenues is estimated to be contributed by markets in North America followed by Europe. This can be attributed to increasing pool of cancer patients along with high healthcare per capita expenditure. The ongoing research and legal initiatives in personalized medicine in Japan could promote the market growth in the country during the forecast period. In markets in Asia pacific and Latin America regions, accelerated development of R&D infrastructure could lead bigger drug makers to create their regional R&D centers focused on personalized medicine during the forecast period. The opening up research in the bioinformatics industry and active peer levels discussion and dialogues are factors that contribute to sustainable growth of the personalized medicines market in the medium to long term.

Personalized Medicine Market: Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE -All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Follow this link:
Personalized Medicine Market - Global Industry Analysis, Size ...

Stem cell therapy is a form of regenerative medicine that utilizes the bodys natural healing mechanism to treat various conditions.

Stem cells are being used in regenerative medicine to renew and repair diseased or damaged tissues, and have shown promising results in treatments of various orthopedic, cardiovascular, neuromuscular and autoimmune conditions.

Stem cells are present in all of us acting like a repair system for the body. However, with increased age sometimes the optimum amounts of stem cells are not delivered to the injured area. The goal of stem cell therapy is to amplify the natural repair system of the patients body.

There are two major types of stem cells embryonic stem cells and adult stem cells. Embryonic stem cells (ESCs) are stem cells derived from human embryos. They are pluripotent, which means they have the ability to develop into almost any of the various cell types of the body.

As the embryo develops and forms a baby, stem cells are distributed throughout the body where they reside in specific pockets of each tissue, such as the bone marrow and blood. As we age, these cells function to renew old and worn out tissue cells. These are called adult stem cells or somatic stem cells. Like embryonic stem cells, adult stem cells can also replicate into more than one cell type, but their replication is restricted to a limited number of cell types.

The unique self-regeneration and differentiating ability of embryonic stem cells can be used in regenerative medicine. These stem cells can be derived from eggs collected during IVF procedures with informed consent from the patient. However, many questions have been raised on the ethics of destroying a potential human life for the treatment of another.

Adult stem cells are most commonly obtained from the bone marrow, specifically the mesenchymal stem cells, which have the ability to replicate into cells that form the musculoskeletal system such as tendons, ligaments, and articular cartilage. They can be obtained from the iliac crest of the pelvic bone by inserting a needle and extracting the stem cells from the bone marrow.

Currently, stem cell therapy is used to treat various degenerative conditions of the shoulder, knees, hips, and spine. They are also being used in the treatment of various soft tissue (muscle, ligaments and tendons) as well as bone-related injuries.

You may be a good candidate for stem cell therapy if you have been suffering from joint pain and want to improve your quality of life while avoiding complications related to invasive surgical procedures.

The procedure begins with your doctor extracting stem cells from your own bone marrow. Bone marrow is usually aspirated from your hip region. Your doctor will first clean and numb your hip area. A needle is then introduced into an area of your pelvic bone known as the iliac crest. Bone marrow is then aspirated using a special syringe and the sample obtained is sent to the laboratory. In the laboratory, the aspirate is spun in a machine for 10 to 15 minutes and a concentrated stem cell sample is separated.

Your doctor then cleans and numbs your affected area to be treated and then, under the guidance of special x-rays, injects the stem cells into the diseased region. The whole procedure usually takes less than one hour and you may return home on the same day of the procedure.

The disadvantage of adult stem cell therapy is lack of data about its long-term effects as it is a newer evolving therapy.

Stem cell therapy is generally considered a safe procedure with minimal complications, however, as with any medical procedure, complications can occur.

Some risks factors related to stem cell therapy include infection as the stem cells may become contaminated with bacteria, viruses or other pathogens that may cause disease during the preparation process.

The procedure to either remove or inject the cells also has the risk of introducing an infection to the damaged tissue into which they are injected. Rarely, an immune reaction may occur from injected stem cells.

Read more:
Regenerative Medicine New York | Stem Cell Therapy

November 14 15, 2018 Harvard Medical School, Boston, MA

We need to make the transition to a predict, prevent and protect health system.

Joshua Ofman, M.D., M.S.H.S.Senior Vice President, Global Value, Access and Policy, Amgen

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 a.m.

Setting the Stage: Exploring the Promise of Personalized Medicine A Keynote Address

SPEAKER | Elizabeth Nabel, M.D., President, Brigham and Womens Hospital

8:55 a.m.

Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine

Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine but they need to know what works and what doesnt if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.

MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine

Ora Dar, Ph.D., Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority

Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England

Marc LePage, President, CEO, Genome Canada

Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

10:10 a.m.

Networking Break

Light refreshments provided.

10:40 a.m.

Evaluating Patients Priorities: Understanding Perspectives on Personalized Medicine A Fireside Chat

MODERATOR | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition

Emily Kramer-Golinkoff, Co-Founder, Emilys Entourage, cystic fibrosis patient

Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; stage IV prostate cancer patient

11:10 a.m.

Automating Actionable: How Artificial Intelligence May Chart a Course for Personalized Medicine

Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes and what that might mean for the future of health care.

MODERATOR | Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare

Tom Miller, Managing Partner, GreyBird Ventures LLC

Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

1:40 p.m.

The Lay of the Lab: Exploring the State of the Clinical Laboratory Testing Industry A Keynote Address

SPEAKER | David King, J.D., Chairman, CEO, LabCorp

2:25 p.m.

The Diagnostics Discussion: Evaluating the Extent to Which the Regulatory and Reimbursement Environment for Diagnostic Tests May Help or Hinder Personalized Medicine

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.

MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates

Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine

Julie Khani, President, American Clinical Laboratory Association

Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

3:25 p.m.

Networking Break

Light refreshments provided.

Sponsored By

3:55 p.m.

Examining Policies: Exploring How Emerging U.S. Regulatory Approaches May Help Facilitate Personalized Care Regimens

The U.S. Food and Drug Administration (FDA) remains firmly committed to regulatory strategies designed to advance personalized medicine. During this wide-ranging fireside chat, two senior leaders from government and industry will discuss the agencys latest actions impacting the oversight of personalized medicine products and services. The discussion will cover topics including but not limited to next-generation sequencing, diagnostic test regulation, digital health, and real-world evidence.

MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson

Lauren Silvis, J.D., Chief of Staff, Immediate Office of the Commissioner, FDA

4:55 p.m.

Engaging Everyone: Leveraging Diversity and Facilitating Equitable Access to Personalized Care

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, four panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute

Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute

Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

Adolph P. Falcn, Executive Vice President, National Alliance for Hispanic Health

Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum

5:55 p.m.

Closing Remarks

SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

6:10 p.m.

Departure for the Museum of Fine Arts, Boston

6:30 p.m.

Welcome Reception at the Museum of Fine Arts, Boston

Avenue of the Arts465 Huntington AvenueBoston, MA 02115

Sponsored by

We will convene for cocktails and hors doeuvres at the Boston Museum of Fine Arts immediately after the first day of conference programming. The museum is in walking distance from the Conference Center.

Sponsored by

6:05 p.m.

Sponsored by

The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Harvard Medical School

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics U.S. Inc; Board Chair, Personalized Medicine Coalition

8:10 a.m.

Pioneering Precision: Inside the Pharmaceutical Industrys Push Toward Personalized Medicine A Fireside Chat

MODERATOR | Meg Tirrell, Reporter, CNBC

Daniel ODay, CEO, Roche Pharmaceuticals

8:55 a.m.

Considering Costs: Evaluating Emerging Pharmaceutical and Insurance Industry Business Models in Personalized Medicine

The pharmaceutical industry is deeply invested in commercializing personalized therapies that must recoup fixed development costs from smaller patient populations covered by health insurance companies that are increasingly concerned about rising health care costs. In that context, this diverse panel will explore the viability of the business model for developing and paying for personalized medicines, tackling issues related to costs, prices, and access.

MODERATOR | Meg Tirrell, Reporter, CNBC

Read more:
2018 Schedule 15th Annual Personalized Medicine Conference

NLM ID: 101574143Index Copernicus Value 2016: 84.15

Genetic Syndromes & Gene Therapy is an official peer-reviewed journal for the rapid publication of innovative research covering all aspects of Gene Mapping and Gene Therapy. Genetic Syndromes, Gene Mapping & Gene Therapy with highest impact factor offers Open Access option to meet the needs of authors and maximize article visibility and creates a platform for the authors to make their contribution towards the journal and the editorial office promises a peer review process for the submitted manuscripts for the quality of publishing.

Genetic Syndromes & Gene Therapy Journal is one of the best open access journals that aims to publish the most complete and reliable source of information on discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in the field and provide online access to the researchers worldwide without any restrictions or subscriptions.

Journal of Genetic Syndromes & Gene Therapy encompasses the continuous coverage of all biological and medical aspects of potential gene therapies for the birth defects along with genetic disorders which include treatments for cancers, arthritis, infectious diseases, inherited diseases like cystic fibrosis and Huntingtons disease, and also genetic abnormalities or deficiencies treated by incorporating specific engineered genes into the infected cells of patients body to people in electronic forms are immediately freely available to read download and share to improve the Open Access motto. The Journal of Genetic Syndromes & Gene Therapy provides reliable information updating online viewers with the modified methods and latest advancements in the field of gene therapy for diverse genetic disorders.

This Genetics journal is using Editorial Manager System for online manuscript submission, review and tracking. Editorial board members of the Genetic Syndromes & Gene Therapy or outside experts review manuscripts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript.

Environmental pollution is "the tainting of the physical and organic segments of the earth/air framework to such a degree, that ordinary natural procedures are antagonistically influenced.

Pollution is the introduction of pollutants into the environment that can cause harm or uneasiness to mankind or other living creatures and can also adversely affect usefulness of a resources of earth. Pollutants can be synthetic substances, or energy, for example: noise, heat or light.

Different types os Environmental pollution are:Air pollution, Water pollution, Noise pollution, Light pollution, Soil pollution, Radioactive pollution, Thermal pollution, Plastic pollution etc.

Down syndrome is one of the most common genetic disorder that affects both physical and mental ability. It is caused by a gene problem before birth.Generally a normal person posses 46 chromosomes but a person with Down Syndrome has 47 chromosomes.There are three different types of Down syndrome: trisomy, translocation, and mosaicism. Symptoms include short head,short neck,poor muscle tone, excessive flexibility etc.

Down Syndrome results when each cell in the body possess three copies of chromosome 21 instead of two copies. Extra copies of genes on chromosome 21 results in the disruption of normal function and development of the body which increases the risk of health problems. Down Syndrome occurs when part of chromosome gets attached to another chromosome during the formation of reproductive cells or embryo. Affected people possess two normal copies of chromosome 21 and one extra chromosome that is attatched to other.

Related Journals of Down Syndrome

Journal of Down Syndrome & Chromosome Abnormalities,Genetic Engineering, Stem Cell,American Journal of Medical Genetics, Down Syndrome Research and Practice,International Journal of Down Syndrome, International Medical Review on Down Syndrome, Down Syndrome Victoria, Journal of Intellectual Disability Research, Down syndrome Journals, Faseb Journal, Fetal Diagnosis and Therapy,Research paper on Down Syndrome,Latest Research on Down Syndrome

Genetic mutation is a permanent change in the DNA.Mutations may or may not produce changes in the organism.Hereditary mutations and Somatic mutations are the two types of Gene mutations.Former type is inherited from the parents and are present in every cell of the human body whereas latter type may occur at some point of life time due to environmental factors.

Certain enzymes repair gene mutations that could cause a genetic disorder. These enzymes identify and repair mistakes in DNA before the gene is expressed and an altered protein is produced. When a mutation alters a protein, it can disrupt normal development. Mutation may occur from a single DNA to a large segment of chromosome that involves multiple genes.

Related Journals of Genetic Mutations

Genetic Medicine, Genetic Engineering,Mutation Research/Genetic Toxicology and Environmental Mutagenesis, European Journal of Human Genetics, Genetics in Medicine, Human Mutation, Human Molecular Genetics, Genetic mutations Journals, Journal of Genetic Counseling,Genetic Journals, Genetic Disorder Articles,Journal of Genetic Mutation Disorders

Sickel cell anemia is a blood disorder caused by an abnormality in haemoglobin molecule in red blood cells.Person inherited by Sickle-cell disease has two abnormal copies of haemoglobin gene.Normal red blood cells are round and flexible whereas sickled red blood cells appear in sickle-shape.Abnormal haemoglobin forms strands that change red blood cells to that form and hence they accumulate at the branches of the veins and blocks the flow of blood.As haemoglobin is responsible for carrying of oxygen throught out the body,there may be chronic attacks due to lack of oxygen supply.

Mutations in HBB gene results in Sickle Cell disease. Haemoglobin consists of four subunits.Two subunits are Alpha-globin and other two are Beta-globin. HBB gene is responsible for making instructions in the production of Beta-globin. Hence mutations in HBB gene results in different abnormal versions of beta-globin.These abnormal versions may distort red blood cells into sickle shape.

Related Journals of Sickel Cell Anemia

Genetic Medicine, Genetic Engineering,Blood, American Journal of Epidemiology, American Society of Hematology, Journal of Clinical Pathology, Human Molecular Genetics, New England Journal of Medicine Science, Sickel cell anemia Journals

It is a type of disease that causes progressive weakness and loss of muscle mass. Here the process of mutation get involved in the production of proteins that are required to build a healthy muscle.Some types of Muscular dystrophy are Myotonic, Facioscapulohumeral , Congenital, Limb-girdle. It occurs when one of the genes responsible for production of proteins is defective.But some of them occur in the early stage of embryo and is passed to the next generation.

Duchenne Muscular Dystrophy is the most common form and mostly affect boys. It is caused due to the absence of dystrophin,a protein involved in maintining the integrity of muscle. Facioscapulohumeral Muscular Dystrophy generally begins at the teenage age and causes progressive weakness in muscles of face, arms, legs, shoulders and chest. Myotonic Muscular Dystrophy is the most common form and causes cataracts, cardiac abnormalities and endocrine substances.

Related Journals of Muscular Dystrophy

Carcinogenesis, Genetic Engineering,Journal of Medical Genetics, Molecular Therapy, Human Molecular Genetics, Human Genetics, American Journal of Human Genetics, PLOS Currents: Muscular Dystrophy, Muscular dystrophy Journals

Cystic fibrosis is a disorder caused by the presence of mutations in both the copies of the gene which is responsible for the protein cystic fibrosis transmembrane conductance regulator.It affects the cells that produce mucus, sweat and digestive juices.These fluids are thin and slippery but a defective gene causes these secretions to become thick ,thus blocking the passages in the lungs and pancreas.

Mutations in CFTR gene results in Cystic fibrosis. CFTR gene enables instructions for transportation of chloride ions into and out of the cells. Mutations in the CFTR gene disrupts the function of chloride channels that prevents the flow of chloride ions and water across cell membranes. As a result organs produce mucus that is thick and sticky which clogs the airways and ducts resulting isevere chronic attacks.

Related Journals of Cystic Fibrosis

Carcinogenesis, Genetic Engineering,Journal of Cystic Fibrosis, American Journal of Medical Genetics, European Journal of Human Genetics, American Journal of Human Genetics, American Journal of Respiratory and Critical Care Medicine, Journal of Genetic Counseling

An Auto immune disease develops when the immune system responsible for defending the body against diseases fights against the healthy cells. Here the immune system fails to differentiate healthy tissues and antigens, as a result the body sets off a reaction that destroy normal tissues.Some unknown trigger happens to confuse the immune system and instead of fighting against the infections it destroys the bodys own tissues.

Areas often affected by autoimmune disease include blood vessels, connective tissues, endocrine glands, joints, muscles, red blood cells, skin. Some common symptoms of autoimmune disease include fatigue, fever, joint pain, and rash. Some common autoimmune disorders include Addisons disease, Multiple Sclerosis, Type 1 diabetes, Sjogren syndrome, Reactive Arthritis, Dermatomyositis, Pernicious anemia, Celiac disease. This disorder may result in destruction of body tissue, abnormal growth of an organ, changes in organ function.

Related Journals of Auto immune Disease

Genetic Medicine, Genetic Engineering,Journal of Autoimmunity, Journal of Autoimmune Diseases, Journal of Autoimmune Diseases and Rheumatology, Open Journal of Rheumatology and Autoimmune Diseases, Advances in Immunology, International Immunology, Auto immune disease Journals

Mitochiondrial disease is a group of disorder caused by dysfunctional mitochondria. Mytochondria are responsible for generation of 90% of energy required by the body to sustain life and growth.These are also known as the power house of the cell.They contain tiny packages of enzymes that converts nutrients into energy. This disease is caused by mutations in mitochondrial DNA and its failure in function may ultimately lead to cell death.

Symptoms include loss of motor control, muscle weakness and pain,swallowing difficulties,liver disease,diabetes,cardiac disease,gastro-intestinal disorders and developmental delay.Ecamples on mitochondrial diseases include dementia,Diabetes mellitus and deafness,Leigh syndrome,neuropathy,Myoclonic epilepsy,strke-like symptoms,mtDNA deletion.

Related Journals of Mitochiondrial Disease

Genetic Engineering, Stem Cell, Mitochondrion, Disease and Molecular Medicine, International Review of Cytology-a Survey of Cell Biology, Journal of Inherited Metabolic Disease, Journal of Bioenergetics and Biomembranes, Molecular Genetics and Metabolism, Mitochiondrial disease Journals

Congenial syndromes is a disease that exists before birth.These are characterized by structural deformities and defects are involved in developing fetus.Defects may be due to genetic or environmental factors.The outcome of the disorder may be because of mothers diet, vitamin intake,glucose levels prior to ovulation. Paternal exposures prior to conception and during pregnancy increases the risk of this disease.It is caused by multiple mutations of the fibroblast growth factor receptor 2 gene.

Defects may include errors of morphogenesis,infection,epigenetic modifications or a chromosomal abnormality.The causes of this syndrome may be due to Fetal alcohol exposure,Toxic substances,Paternal smoking,Infections,Lack of nutrients,Physical restraint,Genetic causes,Socioeconomic status,Role of radiation,Fathers age.

Related Journals of Congenial Syndromes

Genetic Engineering, Stem Cell,Abdominal Imaging, Nature Genetics, Community Genetics, Faseb Journal, Mammalian Genome, Journal of Theoretical and Philosophical Psychology, Congunial syndromes Journals

Reye syndromes is a disease that causes swelling of the brainand liver .The actual cause is unknown but studies has shown that Aspirin is related to the cause of this disease generally in children and teenagers recovering from flu illness.The symptoms are vomiting, nausea, confusion,lethargy,coma, irritable and aggressive behavior.Abnormal laboratoty tests include rise in lever enzymes, ammonia levels and low serum glucose levels.

It is believed that tiny structures within the cell called the mitochondria become damaged. Mitochondria provide cells with energy to the liver for many of the vital functions such as filtering toxins from blood and regulating blood sugar levels. Failure of energy supply to the liver may result in build up of toxic chemicals in the blood which can damage the entire body.It is often seen in children ages 4 to 12. Symptoms are so mild that they go unnoticed. Early detection and treatment are critical but the chances for a successful recovery are greater when Reye Syndrome is treated at its earliest stages. Complications may include coma, permanent brain damage, seizures.

Related Journals of Reye Syndromes

Carcinogenesis, Genetic Engineering,Brain & Development, Annals of Neurology, Journal of Pediatric Gastroenterology & Nutrition, Brazilian Journal of Infectious Diseases, Archives of Disease in Childhood, Journal of The Neurological Sciences, Reye syndromes Journals

Patau syndromes is a disorder caused by chromosomal abnormality.It occurs when some or all the cells contain extra copy of the chromosome 13.This restricts the normal functioning ,growth and development of the organs resulting in intellectual disability and physical abnormalities. It is also called Trisomy 13.It also can occur when part of chromosome gets attatched to another chromosome during the formation of embryo.

Most cases of trisomy 13 are not inherited and results from the random events during the formation of eggs and sperm. An error in cell division may result in abnormal number of chromosome. If this extra copy contributes in the genetic makeup of child then the child possess an extra chromosome 13 in each cell of the body resulting in the physical abnormalities in most of the parts.

Related Journals of Patau Syndromes

Genetic Engineering, Stem Cell,Brain Research, Annals of Human Genetics, Prenatal Diagnosis, Clinical Dysmorphology, Fetal Diagnosis and Therapy, Journal of Intellectual Disability Research, Patau syndromes Journals

Fragile syndrome is a genetic disorder that results in intellectual disability.Mutations in the FMRI gene causes this disease. This gene is responsible for the preparation of a protein ,FMRP.This protein regulates the production of other proteins and is necessary for the development of synapses which are the connections between nerve cells.Mutations in FMRI prevents the production of FMRP ,thus disturbing the nervous system.

Males are severely affected by this disorder than females.Affected individuals usually have delayed development of speech and language by age 2.Children with fragile X syndrome may also have anxietyand hyperactive behavior such as impulsive actions. Fragile X syndrome is inherited in an X-linked dominant pattern. This condition is considered as X-linked since the mutated gene that causes the disorder is located on X chromosome.

Related Journals of Fragile Syndrome

Genetic Engineering, Stem Cell,Human Genetics, American Journal of Medical Genetics, Human Molecular Genetics, American Journal of Human Genetics, Nature Genetics, Journal of Medical Genetics, Fragile syndrome Journals

Angelman syndrome is a genetic disorder that affects the nervous system.Characteristic features include happy demeanor,intelluctual disability,speech impairment,walking and balancing disorders.This arises when segment of the maternal chromosome 15 containing the gene UBE3 A is deleted or undergoes mutation.People inherit one copy of this gene from each parent and both the copies remain active in many of the body tissues.But due to genetic mutations, gene may become active or get deleted in some parts of the brain resulting in intellectual disability.

Angelman Syndrome may also be caused by a chromosomal rearrangement called a translocation or by a mutation or other defect in the region of DNA that controls the activation of UBE3A gene. In some people with angelman syndrome the loss of a gene called OCA2 is associated with light colored hair and fair skin. This gene is located on the segment of chromosome 15 that is deleted in people with this disorder. Most cases of this syndrome are not inherited.

Related Journals of Angelman Syndrome

Carcinogenesis, Genetic Engineering,European Journal of Human Genetics, Brain & Development, Journal of Child Neurology, Cytogenetic and Genome Research, Neurobiology of Disease, American Journal on Mental Retardation, Angelman syndrome Journals

Tay-Sachs is a genetic disorder that destroys the nerve cells in the brain and spinal cord. Characteristic features include weakening of muscles,intellectual disability,vision and hearing loss,paralyses.Mutations in the HEXA gene causes this disease .This gene is responsible for the production of an enzyme in lysosome which plays a critical role in the brain and spinal cord.This enzyme breaks down the toxic substances in the cell.Mutations in the HEXA gene causes failure in the production of enzyme resulting in the accumulation of toxic substances in the cells leading to damage in the neurons of the brain and spinal cord.

Since Tay-Sachs disease impairs the function of a lysosomal enzyme this condition is sometimes referred to as a lysosomal storage disorder.This condition is inherited in which both the copies if the gene undergoes mutations. Persons with Tay- Sachs disease experience vision and hearing loss, intellectual disability and paralysis. An eye abnormality called a cherry-red spot is the characteristic feature of this disorder.

Related Journals of Tay-Sachs

Carcinogenesis, Genetic Engineering,Human Molecular Genetics, Sao Paulo Medical Journal, Journal of Neurochemistry, Journal of Molecular Biology, New England Journal of Medicine, Mammalian Genome - MAMM GENOME, Tay-Sachs Journals

Prenatal genetic testing is meant to evaluate the chance of exhibiting genetic disorders in their unborn children.The tests are usually done between 10th and 13th week of pregnancy . These tests involves the measurement of certain levels of substances in the mothers blood and obtaining an ultrasound.These tests are meant to evaluate the genetic material of the fetus for any genetic disorders.It is also useful to diagnose high risk pregnancies.

Genetic tests are performed on a sample of blood,hair,skin,amniotic fluid or other tissue.A positive test result means that the laboratory found a change in a particular gene, chromosome or a protein. A negative test result means that the laboratory did not find a change in the gene, chromosome or a protein that is under consideration.

Related Journals of Prenatal Genetic Testing

Carcinogenesis, Genetic Engineering,Obstetrics & Gynecology, Genetic Testing, Fetal Diagnosis and Therapy, Clinical Genetics, Prenatal Diagnosis, Journal of Midwifery & Womens Health, Prenatal genetic testing Journals,Genetic Testing Articles,Genetic Journals

Genes hold DNA that are responsible for giving instructions in the production of proteins.Mutations in genes may cause failure in the working of proteins leading to a condition called genetic disorder.These disorders may be inherited form parents or may occur at any point of lifetime.Genetic disorder may result in the addition or reduction in the number of chromosomes.

The four groups of genetic disorders are Single gene disorders, chromosome abnormalities, mitochondrial disorders, and multifactorial disorders. The four main ways of inheriting an altered gene are autosomal dominant, autosomal recessive, X-linked dominant and X-linked recessive. Genetic disorders may or may not be heritable. In non-heritable genetic disorders defects may be due to mutations in the DNA.

Related Journals of Genetic Disorders

Genetic Engineering, Stem Cell, Journal of Genetic Disorders & Genetic Reports, Journal of Medical Genetics, Journal of Genetic Mutation Disorders, Source Journal of Genetic Disorders, Genetic Disorders, Genes and Diseases, Genetic disorders Journals,Genetic Disorder Articles

Go here to see the original:
Journal of Genetic Syndromes & Gene Therapy

Color blindness (or colour blindness or more specific color vision deficiency (CVD)) is well known but hard to imagine if you are not suffering from it. So usually people are either looking for more information to learn about color blindness and all its details, would like to better understand the vision by simulating it or want to test themselves with some form of color blindness test. All this you can be found here on color-blindness.com and much more.

Color blindness affects approximately every 1 in 12 men (8%) and 1 in 200 women (0.5%). This means there is definitely one in your neighborhood or school class affected by it. Most of them are male, because the most common form called red-green color blindness (a term wich is also misleading) is encoded on the x-chromosome and therefore sex-linked. As red-green color blindness is inherited from a mother to her son, a father never passes this type of color blindness on to his children.

The term red-green color blindness is often used but actually not quite correct. Ever type of color vision deficiency affects the whole color spectrum and therefore can not be reduced to just certain colors. Of course, for the most often encountered types Protanomly (the milder form or red-weakness) or Protanopia (missing red cones, red-blindness) and Deuteranomaly (green-weakness) or Deuteranopia (green-blindness) the colors red and green are the most problematic and misinterpreted or indistinguishable ones. But people suffering from any of those forms have issues with the red or green part in every color, so the whole spectrum of colors is affected.

Besides red-green color blindness, which is encoded on the x-chromosome (sex-linked) and therefore much more common for men, there are also forms of color vision deficiency which are evenly distributed between male and female like Tritanomaly (blue-weakness) or Tritanopia (blue-blindness) and the real color blindness Achromatopsia (monochromacy) or the so called blue-cone monochromacy (only blue cones).

Color blindness simulation is fascinating! If you are not colorblind it is so hard to imagine what it looks like to be colorblind: Which color do you see? Do you see any at all? What does it mean not to be able to see red? and so on. My COlor BLIndness Simulator is a handy tool which allows you to use your own images and try out all the different simulation types. It is even possible to save any simulated image and have a one-by-one comparison.

Online color blindness testing is often done but unfortunately no yet as good as it could be. Usually youll find out about color blindness at school or when visiting an eye specialist and want to confirm this with some online tools. There are online color blindness tests available, but most of them are not reliable and cannot compensate a visit at your eye specialist. There is a new form of color blindness test coming up: Color Blind Check uses a new method and its results look very promising. But this new form still needs more time to develop and calibration to count as a trustable color blindness test.

View post:
Colblindor All about Color Blindness

By cultivating the rare and unique Uttwiler Sptlauber apple, scientists have discovered an innovative way to harness this unique plants stem cells to help prevent the look of aging skin by incorporating it into topical anti-aging skincare products. LifeCells breakthrough formula contains Malus Domestica Plant Stem Cells created to replicate the anti-aging effects of this rare Swiss apple.

New innovations allow us to see the skin preserving potential plant stem cells have to offer. Plant stem cells can serve as a sort of internal repair system, dividing essentially without limit to replenish other cells. One of their main characteristics is its ability to protect the longevity of skin by helping combat chronological aging.

What was keeping these apples alive?, What was the secret to such prolonged youth?

And, naturally, how quickly could this miracle ingredient be harnessed to stop the aging process - in people?

Scientists discovered that the key to the apple's longevity lay chiefly in its unusually resilient stem cells. Stem cells in plants function much as they do in people: Their job is to maintain and repair. Stem cells found in skin have a limited life span, and as we age and as we expose ourselves to inevitable environmental assaults - like UV light, i.e., sunshine - they decrease in number, as does their ability to regenerate tissue. The result is the familiar loss of skin elasticity and radiance, and finally wrinkles.

Welcome to the apple. New technology made it possible to replicate the cells of the nearly extinct Uttwiler Sptlauber in the lab. In clinical tests, the apple's stem cells appeared to be protecting the skin. Like a youth tonic, they were nourishing and stimulating them, defending them from UV radiation (like a natural SPF booster), even delaying their aging and death.

And so, this fairly tale has a happy ending. Today, the rare Uttwiler Sptlauber trees (there are now seven) are protected by the European environmental group ProSpecieRara. The apples themselves are so revered, in 2008, the Swiss government put them on a postage stamp. Maybe someday we'll even eat them. Imagine what that could do for you.

View post:
LifeCell Official Site | The All in One Anti Aging Cream

Blue Zones are regions of the world where Dan Buettner claims people live much longer than average. The term first appeared in the November 2005 National Geographic magazine cover story "The Secrets of a Long Life" by Buettner.[1] He identified five areas that Buettner considers "Blue Zones": Okinawa (Japan); Sardinia (Italy); Nicoya (Costa Rica); Icaria (Greece) and among the Seventh-day Adventists in Loma Linda, California. He offers an explanation, based on data and first hand observations, as to why these populations live healthier and longer lives. The term "Blue Zones" is trademarked by Dan Buettner.[2]

The concept grew out of demographic work done by Gianni Pes and Michel Poulain[3] outlined in the Journal of Experimental Gerontology,[4] who identified Sardinia's Nuoro province as the region with the highest concentration of male centenarians. As the two men zeroed in on the cluster of villages with the highest longevity, they drew concentric blue circles on the map and began referring to the area inside the circle as the Blue Zone. Together with demographers Pes and Poulain, Buettner broadened the term, applying it to validated longevity areas of Okinawa, Japan and among the Seventh-day Adventists in Loma Linda, California. Buettner and Poulain, under the aegis of National Geographic, then identified and validated longevity hotspots in Nicoya, Costa Rica and Icaria, Greece.

The five regions identified and discussed by Buettner in the book The Blue Zones: Lessons for Living Longer from the People Who've Lived the Longest:[5]

Residents of these places produce a high rate of centenarians, suffer a fraction of the diseases that commonly kill people in other parts of the developed world, and enjoy more years of good health.[11]

The people inhabiting Blue Zones share common lifestyle characteristics that contribute to their longevity. The Venn diagram at the right highlights the following six shared characteristics among the people of Okinawa, Sardinia, and Loma Linda Blue Zones:[12]

In his book, Buettner provides a list of nine lessons, covering the lifestyle of blue zones people:[13]

Link:
Blue Zone - Wikipedia

At Integrative Medical NY, patients find a wide range of services to heal from chronic disease, gain more energy, and live fuller, healthier lives. With an emphasis on functional, holistic, and integrative medicine, the practice serves individuals in New York City and the surrounding communities.

The foundation of functional medicine allows the Integrative Medical NY team to diagnose and treat illness with many different approaches. The practice is led by Dr. Maurice Beer and nurse practitioners Jessica Berarducci, Shoko Karakilic, and Mary Beth Charmo.

Guided by the principle that healthcare should be personalized and unhurried, the team uses a medically-informed model with more natural solutions to help patients heal.

From customized nutrition programs and hormone replacement therapy to mindfulness strategies and lifestyle modifications, the team aims to resolve the cause of disease and provide individuals with a plan to sustain lifelong health.

The providers at Integrative Medical NY know people who understand their bodies are more likely to stay healthy. With a commitment to patient education, mind-body harmony, and demystifying complex medical problems, the practice helps individuals become their health advocates and provides them with tools for long-term well-being.

Continued here:
Integrative Medical NY: Board Certified Internal Medicine ...

An Error Occurred Setting Your User Cookie

This site uses cookies to improve performance. If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly. Below are the most common reasons:

This site uses cookies to improve performance by remembering that you are logged in when you go from page to page. To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.

This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.

In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a website to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it.

Read more:
CT Findings of Late-Onset Noninfectious Pulmonary ...

Abstract

Osteoarthritis (OA) is a chronic degenerative condition of the articular cartilage, which is the most common cause of disability in patients over age 65. Treatment options are limited towards alleviating symptomology.

Mesenchymal stem cells (MSC) are effective at treating osteoarthritis (OA) in animal models and clinical trials [1-6]. Mechanisms of therapeutic activity appear to be associated with regenerative and anti-inflammatory factors produced by MSC [7, 8]. On the one hand, MSC produce soluble factors that are antioxidant [9], antifibrotic [10], and stimulate endogenous chondrogenic progenitors [11], on the other hand MSC directly can differentiate into cartilage tissue [12].

The proposed study will involve intra-articular injection of umbilical cord tissue mesenchymal stem cells (UC-MSC) into joints of 20 patients with grade 2-4 radiographic OA severity and intravenously in 20 patients with grade 2-4 radiographic OA severity. The primary endpoint will be safety and feasibility as assessed by lack of treatment associated adverse events. The secondary endpoint will be improvements in joint function as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Patients will be examined at baseline and 3 and 12 months after treatment.

This, study will provide support for double-blind placebo controlled investigations. The potential of using UC-MSC for this debilitating condition will open the door for future investigations in other inflammatory conditions if results demonstrate safety and feasibility of this approach.

Follow this link:
Human Umbilical Cord Stem Cells for ... - Medistem Panama

As your doctor, I practice medicine in a different way than you may be used to. As medical practices get larger and suffer under increasing insurance restraints, many have come to lack something very importantpersonal attention. Due to sagging reimbursements by insurance companies and higher operating costs, many practices are forced to see many patients every day. I want to care for you on a more personal level.

By keeping my practice small, I can focus first on who you are as a person instead of your illness or symptoms. And youll see only me not a nurse practitioner or other doctorsso you get the attention you deserve in a caring, warm environment.

My practice is based on a partial concierge or membership medicine model. This allows me to limit the number of patients I see and provide the personalized, comprehensive primary care you cant find in most doctors offices.

If you choose to become a member, for an affordable annual fee you can access same- or next-day unrushed appointments that allow me to address all of your questions and concerns. And because youll have ongoing direct communication with me, sometimes you can avoid an appointment altogether, or even a trip to the Emergency Department.

Not ready to become a member yet? Thats okay. Im still happy to see youjust understand that many of these special service benefits are for members only.

My smaller practice allows me to focus on more than treating problems, but also teaching wellness and prevention with the goal of living a long and healthy life free from disease. See our services.

Our healthcare system is filled with plenty of challenges, but having a doctor who can spend enough time with you shouldnt be one of them. I look forward to providing you the attentive, personalized care you have always hoped to find.

Do you have questions? Please call us at (910) 762-4488. Our Patient Membership Coordinator / Office Manager Linda will be happy to help you.

~ Dr. Steve LiederbachBoard Certified, Internal Medicine

Read more:
Wilmington Adult Medicine Personalized Medicine Membership ...

The Veterinary Referral Center of Northern Virginia has provided unmatched, compassionate emergency, internal medicine, and surgery care for dogs and cats and their owners throughout Northern Virginia for more than 30 years. We understand and appreciate the needs of our clientsboth owners and referring veterinariansand do our very best to meet these needs.

We provide exceptional emergency services 24/7 365 days a year, including holidays, and unsurpassed referred internal medicine, surgery, behavior medicine, and ophthalmology services at fees that are often significantly less than other regional referral centers. Our veterinarians are award-winning experts in their fields. Providing our patients and clients with an unparalleled care experience is our top priority.

Our Behavior Medicine Division, added in 2016, is led by Dr. Amy Pike, one of fewer than 70 board-certified veterinary behaviorists in North America. Dr. Amy Butler and Dr. Jocelyn Patterson, two highly regarded critical care specialists, are now members of our team. On July 23, 2018 we added an Ophthalmology Division led by Dr. Michelle Samuel, leading board-certified ophthalmologist.

We are locally owned and operated and give back to our community. Trust our highly trained veterinarians and staff members to care for your beloved four-legged family members.

Read the original post:
Veterinarian in Manassas, Virginia | The Veterinary ...

Age happens. While theres nothing we can do to literally turn back the clock, we can work to optimize your vitality, weight, and sense of well-beingas well as prevent diseaseas you move through life. Medicine moves fast, and every day there are new techniques and treatments being perfected that are effective, safe, and non-invasive. Dr. Kate Kass makes it her highest priority to seek out training and certifications in breakthrough protocols. Be it chronic pain, wrinkles, or decreased energy and vitality, Dr. Kass can work with you to tailor a regenerative treatment program to your specific needs, so you dont have to settle for anything less than your best self.

Hormones decline as we age. In your 40s and 50s, you might receive hormone replacement therapy but HGH, human growth hormone, is often overlooked. The decline in HGH contributes to the acceleration of the aging processwhich includes changes in body composition, bone density, lipid metabolism, cardiovascular function, and physical performance.

Symptoms of low growth hormone can often mimic the symptoms of low testosterone or estrogen. If you have adult HGH deficiency, you could experience one or some of the following symptoms:

A higher level of body fat, especially around the waist

Anxiety and depression

Decreased sexual function and interest

Fatigue

Feelings of isolation

Greater sensitivity to heat and cold

Decreased muscle mass

Less strength and stamina

Reduced bone density

Abnormal changes in cholesterol composition

Not great, right? But the good news is that Dr. Kass offers a thorough protocol to optimize adult growth hormone levels. Testing and restoring adult growth hormone levels is an essential part of Dr. Kass comprehensive age management strategy, and has proven to be safe, affordable, and highly effective. ( Please note, we do not prescribe growth hormone but work with patients on other strategies for improving levels)

Dr. Kass offers a variety of customized IV nutrient infusions that target your specific condition, such as migraines, adrenal fatigue, depression, anxiety, or a sluggish metabolism. IV nutrient therapy is ideal for athletes, patients with compromised gut function, patients who are recovering from illness and need immune support, and anyone looking for an antioxidant boost for regenerative benefits. Dr. Kass offers many different IV nutrient therapy combinations, including:

Originally pioneered for professional athletes in the 1970s to help heal injuries, PRP is now used extensively for orthopedic treatments for regenerating ligaments,tendons, and joint injuries, and in orthopedic surgeries to improve surgical outcomes. PRPs applications are wide-ranging, since it has the ability to regrow collagen, enrich fibrin, and aid in the formation of new blood vessels.

Heres how it works: PRP is a concentrated preparation of your own growth factors extracted from your own blood. When injected into an area of concern, PRP stimulates a stem cell response for regeneration of the target tissue. In her practice,Dr. Kass has harnessed the power of PRP to treat many different longevity concerns. Using one of the leading PRP harvesting systems available, she draws a patients blood, and then runs the blood through a specialized centrifuge to concentrate the patients own platelets and growth factors. This concentrated growth factor soupwith all its amazing healing and restorative propertiesis then injected into targeted areas for regeneration.

Dr. Kass leverages PRP therapy to regrow hair by promoting stem cell regeneration and regrowth of weakened hair follicles. Her protocol combines PRP with ACell, an FDA-approved protein product. ACell provides an extracellular matrix as a kind of scaffolding for stem cells to latch onto and grow, increasing the treatments efficacy and reducing the formation of scar tissue. Injection treatments last 90 minutes and frequently provide results in just one visit. PRP is an effective option for women who are genetically predisposed to hair loss or thinning and men who experience male-pattern baldness.

In addition, Dr. Kass uses PRP therapy to treat other medical concerns ranging from sexual function to scar rejuvenation and damaged skin.

Dr. Kass is one of the few practitioners who is certified and trained in the protocols of the Vampire Facial, a highly sought-after treatment that harnesses PRP and concentrated growth factors to stimulate new collagen and improve skin tone and texture. You will continue to see improvements in your skin for 23 months and results will last for 12 years.

With a foundation in functional medicine, Dr. Kass works with you to determine the root cause for weight gain or an inability to lose weight. She tests for food allergies,and conducts genetic testing to determine the optimal weight-loss strategy for you.She helps you to clean up your gut and correct hormone imbalances. Dr. Kass focuses on shoring up your foundation so you can establish a healthy weight. If you need ongoing assistance, she will work with you to create a medical program and develop meal plans for ongoing weight loss and maintenance.

For these treatments to work optimally, Dr. Kasss Pillars of Functional Wellness always need to be in place. The five Pillars are: gut health, hormone balance,reduced environmental exposure to toxins, emotional well-being, and physical activity. The Pillars of Functional Wellness create a sustainable strategy for long-term health.

Contact Dr. Kass to start living your best life today.

Visit link:
Regenerative Medicine Seattle - Dr. Kate Kass

How much is stem cell therapy? As stated by CBC Canada,the cost of stem cell therapy is $5,000 to $8,000per stem cell treatment for patients. According to a Twitter poll by BioInformant, the cost can be even higher. Our May 2018 poll found that stem cell treatments can cost as much as $25,000 or more. This article explores the key factors that impact the cost of stem cell therapy, including the type of stem cells used within the protocol, the number of treatments required, and the site of theclinic. It also provides pricing quotes from stem cell clinics within the U.S. and worldwide.

In this article:

Stem cell therapy is the use of living cells as therapeutics to treat disease or injury. Read on to learn about the cost requirements of these procedures.

CBC Canadas pricing involves Cell Surgical Network (CSN) following its protocol to remove fat tissue and process it before re-injecting [adipose-derived stem cells] either directly or intravenously into the same patient. Unfortunately, the U.S. FDA and Department of Justice (DOJ) sent this network of stem cell treatment providers a permanent injunction notice in May 2018. Therefore, patients should not seek treatments from the group at this time.Although Cell Surgical Network (CSN) is based in California, it has a network of approximately 100 U.S. treatment centers. They also have three Canadian clinics located in Vancouver, Sudbury,andKamloops.

The controversy such as the one above stirs up questions about the safety of stem cell procedures. Anyone considering stem cell therapy from any tissue or source will benefit from understanding the possible consequences of stem cell therapy and the factors driving costs.

For the patient, a stem cell transplant involves multiple steps, including:

There are also real costs for the doctors who provide stem cell treatments. They have overhead costs, including:

There is also time and expertise required toperform the procedure and offer post-operative care. In some cases, the physician must pay licensing fees to access stem cell sourcing, processing, or delivery technologies.

Stem cell treatment has gained more and more traction over the last decade. It has been helped along by considerable advances in research. In 2017, the number of scientific publications about stem cells surpassed 300,000. The number of stem cell clinical trials has also surpassed4,600 worldwide.

However, stem cell therapy is still expensive. Among the cheapest and easiest options is to harvest adipose-derived stem cells (ADSCs) those that exist in adult fat layers and re-deliver them to the patient. Unlike harvesting from bone marrow or teeth, providers can feasibly remove fat, separate stem cells, then re-inject them into a patient the same day. This approach is typically less expensive than those that require more invasive procedures for harvesting. Because of its practicality in terms of cost, it has become a common approach to stem cell treatment.

Relatively easy harvesting stilldoesnt translate to inexpensive cost, although some are certainly more affordable than others. For orthopedic conditions, the costof stem cell therapy is typically lower, averaging between $5,000 and $8,000. Examples of these types of medical conditions include:

Note that these prices are typically out-of-pocket costs paid by the patientbecause most insurance companies will not cover them. They are considered experimental and unapproved by the FDA. This means patients needing stem cell treatment will need to use their own savings.

Although fat is a frequently utilized source for stem cells, it is also possible for physicians to utilize stem cells from bone marrow. Regenexx provides this service in the U.S. and Cayman Islands. With theRegenexxstem cell injection procedure, a small bone marrow sample is extracted through a needle, and blood is drawn from a vein in the arm. These samples are processed in a laboratory, and the cells it contains are injected into an area of the body that needs repair. On June 19, 2018, ACAP Health, a leading provider in innovative, clinical-based solutions partnered with Regenexx to reduce high-cost musculoskeletal surgeries.ACAP Health is a national leader in employer healthcare expense reduction. It is one of the first healthcare groups to partner with a stem cell treatment group to support insurance coverage to patients.

A recent Twitter poll conducted by BioInformant reported that, on average, patients can expect to spend $25,000 or more on stem cell therapies. According to the poll,

Most likely, those paying lower stem cell treatment costs under $5,000 were pursuing treatment for orthopedic or musculoskeletal conditions. In contrast, those paying higher treatment costs were likely getting treated for systemic or more complex conditions, such as diabetes, multiple sclerosis (MS), neurodegenerative diseases (such as Alzheimers disease or dementia), psoriatic arthritis, as well as the treatment for autism.

In the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes blood drawn from a patient can cost as little as $1,500. However, protocols that utilize a bone marrow or adipose (fat) tissue extraction can run as much as $15,000 $30,000. This is because bone marrow extraction is an invasive procedure that requires a penetrating bone and adipose tissue extraction requires a medical professional trained in liposuction.

For treatments that require a systemic or whole-body approach, the cost tends to be in the higher range, often averaging from $20,000 to $30,000. Examples of the diseases or conditions requiring this type of stem cell treatment include:

These higher costs reflect the complexity of treating these patients and the fact that multiple treatments are often required.

Founded by Dr. Neil Riordan, a globally recognized stem cell expert, theStem Cell Institutein Panama is one of the worlds most trusted adult stem cell therapy centers. Over the past 12 years, the center has performed more than10,000 procedures, making it a widely recognized destination for stem cell treatments.

Working in collaboration with universities and physicians worldwide, its stem cell treatment protocols utilize combinations of allogeneic human umbilical cord blood stem cells and autologous bone marrow stem cells to treat a wide variety of conditions.

A reader of BioInformant was recently treated for psoriatic arthritis at the Stem Cell Institute in Panama in early 2018. The price of his stem cell treatment was $22,000. With travel and lodging included, the total expenses were approximately $30,000.

Because of its proximity to the U.S., Mexico is increasingly becoming a destination for medical tourism.Before choosing a stem cell treatment provider in Mexico, ensure the clinic is fully authorized by COFEPRIS, the Mexican equivalent to the FDA.

One patient who recently shared stem cell treatment quotes with BioInformant found that the treatment for glycogen storage disease, a metabolic disorder that often onsets in infancy and continues into adulthood, would cost $23,900 throughGIOSTAR Mexico.

In contrast, the patient was quoted$33,000 throughCelltex, a U.S.-based company that treats patients in Cancun, Mexico.Celltex follows FDA regulations concerning the export of cells to Mexico and is compliant with the standards and procedures of COFEPRIS. Celltex also has an alliance with a certified hospital in Mexico, which is approved to receive cells and administer them to patients by a licensed physician.

In contrast, the patient was quoted $10,000 from Stem Cell Therapy of Las Vegas and Med Spa, an American clinic. This price difference may reflect regulatory restrictions that prevent U.S. providers from expanding cells. It may also reflect the therapeutic approach used by the clinic, as well as the quality of their expertise.

In Mexico, where certain types of stem cell expansion are allowed that are restricted within the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes peripheral blood from a patient can cost as little as $1,000. In contrast, protocols that utilize more invasive sources of stem cells can run as much as $15,000 $35,000. Examples of invasive procedures includebone marrow and adipose tissue extraction. In some cases, hospitalization may be required, which raises costs. The location of a stem cell facility can factor heavily into thecost of the procedure.

Not every cost associated with treatment gets billed to the patient at the time of the procedure. Hidden costs such as reactions to the treatment, graft-versus-host disease, or disability derived from the treatment can all result in more money to the patient, to insurance, or to the government.

For example, in the case of someone with cancer, it frequently isnt viable to harvest the patients own stem cells because they may contain cancerous cells that can reintroduce tumors to the body. Instead, the patient would receive stem cells by transplant. Treatments that involve cells from another person are called allogeneic treatments. The danger here is that the body may see those cells as invaders and attack them via the immune system, a condition known as graft-versus-host disease (GvHD). The body (host) and the introduced stem cells (graft) then battle rather than coexist.

Transplanted cells often face the risk of being rejected by their host; this article discusses the effect of plasma exchange on acute graft vs. host diseasehttps://t.co/cA3nzFntew

Katie Bunde (@kbuns76) May 29, 2018

In addition to making the stem cell treatments less effective or ineffective, GvHD can be deadly. Roughly30 to 60 percent ofhematopoieticstem cell and bone marrow transplantationpatients sufferfrom it, and of those, 50 percent eventually die. The hospital costs associated with it are substantial.

Another hidden cost is the potential to disrupt a system that formerly functioned adequately. The best current example of this isthe case of Doris Tyler, who received bilateral stem cell injections in her eyes from Drs.RobertHalpernand JamieWalraven of Stem Cell Center of Georgia. According to her, while her vision was failing, it was still good enough to perform various tasks, and now it is not. That means the cost increases for her, as well as potential insurance or disability claims (though again, insurance is unlikely to cover the specific consequences of this action).

Because of tight regulations surrounding stem cell procedures performed in the United States, many stem cell treatment providers provide both on-shore (U.S.-based) and offshore (international) treatment options.Depending on where a treatment is received, patients may have to pay travel, lodging,and miscellaneous expenditures.

For example, Regenexx offers treatments at a wide range of U.S. facilities using non-expanded stem cells. However, it also offers a laboratory-expanded treatment option at a site in the Cayman Islands, which can administer higher cell doses to patients by expanding the cells in culture within a laboratory.

Similarly, Okyanos (pronounced Oh key AH nos) offers treatments to patients at its Florida location and provides more involved stem cell procedures at its offshore site inGrand Bahama. It was founded in 2011 and is a stem cell therapy provider specializing in treatments for congestive heart failure (CHF) and other chronic conditions. It is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.

Similarly, Celltex is headquartered in Houston, Texas, but offers stem cell treatments in Cancun, Mexico. Celltex specializes in storing a patients mesenchymal stem cells (MSCs) for therapeutic use.

While no hard evidence yet points to stem cell clinics raising their rates as a result of lawsuits, that is a typical response in industries whose products or services the public perceives as a high risk.

An additional danger to stem cell treatment providers,points out Nature, is the reduction of bottom-line profits through former patients winning suits. If clinics have to pay out the money they earned and then some to individuals suing for damages, they may soon become faced with an unviable business model. That is a definite concern for those hoping to leverage these treatments now and in the future.

As with any other area of medicine, patient evaluations of stem cell providers and treatments run the gamut from extremely satisfied to desolately unhappy. Those like Doris Tyler who have lost their eyesight exist at the negative end of the spectrum. However, many others praise stem cell treatments for their power to heal diseases, boost immunity, fight cancer, and more.

For example, BioInformants Founder and President, Cade Hildreth, had a favorable experience with stem cell therapy. Cade had bone marrow-derived stem cells collected and then had them re-injected into the knee to treat a devastating orthopedic injury. Cade was able to reverse pain, swelling, and scarring to reclaim an elite athletic ability.

As of now, this much is clear. There exists enough interest in America and across the world that stem cell providers are continuing to offer a wide range of treatments. Stem cell treatments also offer the potential to reverse diseases that traditionally had to be chronically managed by drugs. Like most medical practices, stem cell treatments will require further testing to reveal merits and faults. Until then, the public will likely continue to pursue services when medical needs arise.

Although the cost of stem cell therapy is pricey, some patients choose to undergo the treatment because it is more economical than enduring the costs associated with chronic diseases.

Although most stem cell therapy providers do not provide FDA-approved procedures, the Food and Drug Administration (FDA) continues to encouragepatients to pursue approved therapies, even if there is a higher associated treatment cost.

Providers rarely post their prices for stem cell treatments in print or digital media because they want patients to understand the benefits of therapy before making a price decision. Additionally, the price of stem cell treatments varies by condition, the number of treatments required, and the complexity of the procedure, factors that can make it difficult for medical providers to provide cost estimates without a diagnostic visit for the patient. However, in many cases, it is not in the patients best interest to make treatment decisions based on the cost of stem cell therapy. The best way to know whether to pursue stem cell therapy is to explore patient outcomes by condition and compare the healing process to other surgical and non-surgical treatment options.

The cost of stem cell therapy is indeed expensive, especially because the procedures are rarely covered by health insurance. However, with the right knowledge and a clear understanding of the treatment process, the risk of undergoing stem cell therapy can be worth it, especially if it removes the requirement for a lifetime of prescription medication. Although stem cell therapy has associated risks, it has improved thousands of lives and will continue to play in a key role in the future of modern medicine.

Download this infographic for your reference:

Are you seeking a stem cell treatment? If so, we have partnered with GIOSTAR to help you acccess medical guidance and advice.

In alignment with what we believe at BioInformant, GIOSTARs goal is to offer cutting-edge, extensively researched stem cell therapy options designed to rejuvenate and improve a patients quality of life.

Click here to Schedule a Consultation or ask GIOSTAR a question.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

Do you think the cost of stem cell therapy is too much? Share your thoughts in the comments section below.

Up Next: Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research

Cost Of Stem Cell Therapy And Why Its So Expensive

Continue reading here:
The Cost Of Stem Cell Therapy And Why It's So Expensive ...

Acupuncture

Acupuncture is a technique in which practitioners stimulate specific points on the body - most often by inserting thin needles through the skin. It is one of the most effective practices used in traditional Chinese medicine. Acupuncture stimulates nerve fibers to transmit signals to the spinal cord and brain, activating the bodys central nervous system. The spinal cord and brain then release hormones responsible for making us feel less pain while improving overall health. Acupuncture may also: increase blood circulation and body temperature, affect white blood cell activity (responsible for our immune function), reduce cholesterol and triglyceride levels, and regulate blood sugar levels.

Aquatherapy

Aquatic Physical Therapy is the practice of physical therapy in a specifically designed water pool with a therapist. The unique properties of the aquatic environment enhance interventions for patients with neurological or musculoskeletal conditions. Aquatic therapy includes a wide range of techniques allowing patients to improve their balance, muscle strength and body mechanics. Aquatic therapy works to enhance the rehabilitation process and support effectiveness of stem cell treatment.

Epidural Stimulation

Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy (HBOT) is the medical use of oxygen at a level higher than atmospheric pressure. The equipment required consists of pressure chamber, which may be of rigid or flexible construction, and a means of delivering 100% oxygen into the respiratory system. Published research shows that HBOT increases the lifespan of stem cells after injection and provides an oxygen-rich atmosphere for the body to function at optimum levels.

Nerve Growth Factor (NGF)

Nerve growth factor (NGF) is a member of the neurotrophic factor (neurotrophin, NTFS) family, which can prevent the death of nerve cells and has many features of typical neurotransmitter molecules. NGF plays an important role in the development and growth of nerve cells. NGF is synthesized and secreted by tissues (corneal epithelial, endothelial, and corneal stromal cells), and it can be up-taken by sympathetic or sensory nerve endings and then transported to be stored in neuronal cell bodies where it can promote the growth and differentiation of nerve cells.NGF can exert neurotrophic effects on injured nerves and promote neurogenesis (the process of generating neurons from stem cells) that is closely related to the development and functional maintenance and repair of the central nervous system. It is also capable of promoting the regeneration of injured neurons in the peripheral nervous system, improving the pathology of neurons and protecting the nerves against hypoxia (lack of oxygen)/ischemia (lack of blood supply).

Nutrition Therapy

Occupational Therapy

Occupational therapy interventions focus on adapting the environment, modifying the task and teaching the skill, in order to increase participation in and performance of daily activities, particularly those that are meaningful to the patient with physical, mental, or cognitive disorders. Our Occupational Therapists also focus much of their work on identifying and eliminating environmental barriers to independence and participation in daily activities, similar to everyday life.

Physiotherapy

Physical therapy or physiotherapy (often abbreviated to PT) is a physical medicine and rehabilitation specialty that, by using mechanical force and movements, remediates impairments and promotes mobility, function, and quality of life through examination, diagnosis, prognosis, and physical intervention. We combine our PT with stem cells for maximum physical rehabilitation improvements.

Transcranial Magnetic Stimulation

Research has shown that TMS can effectively treat symptoms of depression, anxiety, neurological pain, stroke, spinal cord injuries, autism and more. This procedure is very simple and noninvasive. During the procedure, a magnetic field generator or coil is placed near the head of the person receiving the treatment. The coil produces small electrical currents in the region of the brain just under the coil via electromagnetic induction. This electrical field causes a change in the transmembrane current of the neuron which leads to depolarization or hyperpolarization of the neuron and the firing of an action potential.

Go here to see the original:
Stem Cell Treatments and Therapies from Beike Biotechnology